Program

Programmet är preliminärt och kan komma att ändras

Måndag 6 februari

10:00-10:15 Welcome to Sweden Liver Week 2023
Andreas Schult
10:15-10:30 Introduction to the dynamics of advanced chronic liver failure
Anna Cederborg
10:30-11:00 Hepatology consultation #1 First decompensation in cirrhosis- What is important to do right now
Ingalill Friis-LibyHelgi Björnsson
11:00-11:45 Hepatology consultation #2 Late decompensation- What can be done still?
Ingalill Friis-LibyHanna ChinHelgi Björnsson
11:45-12:30 Decompensation in children with chronic liver disease
Girish Gupte
13:30-14:00 Pitfalls for radiological assessment of HCC
Mats Andersson
14:00-14:30 Systemic treatment of HCC – what every HPB surgeon should know
Per Stål
14:30-15:00 ASA as prophylaxis for HCC
Jonas Ludvigsson
15:00-15:30 Coffee break
15:30-16:30 Debate: Feasibilities of and prerequisites for curative treatment in HCC
Jacob FreedmanOskar Hemmingsson
13:30-13:35 Välkomna och praktisk information
Karin EdlundMalin Aram
13:35-14:05 Varför transplanteras barn? Indikationer, diagnoser, resultat.
Ulrika HärenstamNils Ekvall
14:05-14:35 ”Jag lever” – en självbiografisk skildring om att vara ung och levertransplanterad, tre gånger
Agnes HultbergMoa Flink
14:35-15:00 Coffee break
15:00-15:30 Utredning, operation och uppföljning av en levande leverdonator
William Bennet
15:30-16:15 Att vara förälder till ett leversjukt barn och plötsligt själv bli patient (levande leverdonator)
Ulrika Pizzeghello Johansson
16:15-16:30 Summering & Utvärdering
16:45-17:45 Cholestatic Liver Disease – From treating cholestasis and pruritus to improving native liver survival
Patrick McKiernanHanns-Ulrich Marschall

Tisdag 7 februari

08:30-09:00 News in PSC: Implications of new guidelines and national highly specialized care (NHV)
Annika Bergquist
09:00-09:40 Diagnosis and treatment of severe alcoholic hepatitis without histological verification. What are the risks?
William Bernal
09:40-10:00 Hepatology consultation #3: Screening for bacterial infections in decompensated cirrhosis (recommendations from Baveno VII)
Antti Oksanen
10:00-10:30 Coffee break
10:30-11:10 State of the Art: Plasmaferesis in acute liver failure, immunological and neurological effects.
Fin Stolze Larsen
11:10-11:50 Hepatology consultation #4: ICU care in ACLF -implication of national highly specialized care (NHV)
Johan WaernJacob HolmqvistMiriam Burthun
11:50-12:30 Hepatology consultation #5: Portosinusoidal vascular disorder (PSVD)
Aurelier Plessier
08:30-08:35 Välkomna
Karin EdlundPia Loqvist
08:35-09:45 PREM och PROM: från mening till mätning – hur man mäter patientperspektiv
Anna Forsberg
09:45-10:15 Coffee break
10:15-11:00 Leverns funktion och dess utredningar
Andreas Schult
11:00-11:40 Omvårdnad enligt Nationella vårdprogrammet för levercirros
Maria Hjorth
11:45-12:15 Mat vid levercirros – vad ger vi för rekommendationer till våra
Catarina Lindkvist
12:15-12:30 Frågor, summering, utvärdering. Välkommen till Stockholm 2024
Karin EdlundMalin AramPia Loqvist
08:30-08:35 Welcome
08:35-09:30 Pruritus treatment in general and news about IBAT-inhibitors
Henrik Arnell
09:30-10:00 Immune dysregulation after liver transplantation
Timo Käppi
10:00-10:30 Coffee break
10:30-11:15 Drug Induced Liver Injury (DILI)
Girish Gupte
11:15-11:45 UK-hepatitis
Girish Gupte
11:45-12:30 Case-discussion
13:30-15:00 Acute and acute-on-chronic liver failure
Chair(s): Andreas SchultAntti Oksanen
13:30-14:15 State of the Art: Liver Transplantation for Acute Liver Failure
William Bernal
14:15-14:45 Liver Transplantation for ACLF grade 3 – Feasibility and Futility
Maria Antonella Burza
14:45-15:00 Results for National Prioritization for LT in ACLF grade 3
Andreas Schult
15:00-15:30 Coffee break
15:30-17:00 Liver transplantation – Expanding the donor pool
Chair(s): Ming YaoWilliam Bennet
15:30-15:55 ABO-incompatible liver transplantation for selected non-emergency cases?
Ulrika Skogsberg
15:55-16:20 Liver Grafts from DCD donors – An opportunity for everyone?
Gabriel Oniscu
16:20-17:00 Implementation of DCD for liver transplantation in Sweden
Carl Jorns
13:30-14:15 High content imaging in patient-derived models
Brinton Seashore-Ludlow
14:15-15:00 Liver-on-chips for improved drug screening and disease-on-chip
Caroline Adiels
15:00-15:30 Coffee break
15:30-15:50 Fire Talk: The mitochondrial amidoxime-reducing component 1 pAla165Thr reduces protein stability
Ester Ciociola
15:50-16:10 Fire Talk: Interleukin 32 downregulation lowers hepatocyte lipid content by reducing de novo triglyceride synthesis
Kavitha Sasidharan
16:10-16:30 Fire Talk: Unsupervised machine learning of MRI radiomics features for liver function stratification
Qiang Wang
16:30-17:15 Transcriptional guardian of lipid metabolism in liver diseases
Claudia Kutter

Onsdag 8 februari

08:45-09:30 Hepatic IKKẞ deletion improves fatty liver and insulin sensitivity
Vagner Ramon Silva
09:30-09:50 Fire Talk: Hepatocyte-specific depletion of the corepressor GPS2 alleviates atherosclerosis and dyslipidemia in mice
Sviatlana Sukhanava
09:50-10:10 Fire Talk: Does CD36 link hepatocyte cell proliferation and lipid metabolism?
Katharina Kuentzel
10:10-10:30 Fire Talk: Isotope tracing and metabolic flux analysis in human liver tissue ex vivo
Roland Nilsson
10:30-11:00 Coffee break
11:00-11:45 Micro- and nanostructures for biopsies, therapy and in-vitro modelling of pancreas and liver
Wouter van den Wijngaart
11:45-12:30 The employment of systems biology in treatment of NAFLD
Cheng Zhang
09:00-09:30 Screening in hepatology: Should we screen risk groups for advanced liver disease? (Pro/Con)
Per StålStergios Kechagias
09:30-09:50 Novel image-based biomarkers for non-invasive liver characterization
Hanna Hebelka
09:50-10:20 Hepatology consultation #6: Management of hemestasis and portal vein thrombosis in cirrhosis
Maria Magnusson
10:20-10:50 Coffee break
10:50-11:30 Use of albumin in advanced liver disease today and tomorrow
Anna CederborgAntti Oksanen
11:30-12:15 Summary of 2022 in Swedish hepatology och transplantation: Lessons from past and future directions
William BennetAnnika Bergquist
12:15-12:30 Concluding remarks
Per Stål